MedTrace Logo

Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis

NCT02131051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2014-05-06

No results posted yet for this study

Summary

This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops. In addition the effectiveness and safety shall be compared to Azelastine containing nasal Sprays and Eye drops. The patient applied Ectoin® Rhinitis Nasal Spray / Eye drops or takes Azelastine nasals spray and eye drops according to the instructions for use. The observation takes place over a period of 7 days. Response to treatment is recorded at day 7 by the physician and in daily by the patient in a dairy.

Conditions

  • Allergic Rhinoconjunctivitis

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Principal Investigators

  • Uwe Sonnemann, MD · HNO Praxis Elmshorn

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131051 on ClinicalTrials.gov